SEC Comment Letter 0000000000-25-003638 to Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech, Inc.
Date: April 4, 2025 · CIK: 0001659617 · Accession: 0000000000-25-003638

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-286276

Date

April 4, 2025

Author

Walter Klemp

Form

UPLOAD

Company

Moleculin Biotech, Inc.

Letter

April 4, 2025 Walter Klemp Chief Executive Officer Moleculin Biotech, Inc. 5300 Memorial Drive, Suite 950 Houston, TX 77007 Re:Moleculin Biotech, Inc. Registration Statement on Form S-1 Filed March 31, 2025 File No. 333-286276 Dear Walter Klemp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Cavas S. Pavri

Show Raw Text

April 4, 2025
Walter Klemp
Chief Executive Officer
Moleculin Biotech, Inc.
5300 Memorial Drive, Suite 950
Houston, TX 77007
Re:Moleculin Biotech, Inc.
Registration Statement on Form S-1
Filed March 31, 2025
File No. 333-286276
Dear Walter Klemp:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Cavas S. Pavri

SecProbe.io